Vanguard Group Inc Moleculin Biotech, Inc. Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.85 - $16.65 $510 - $9,990	600 Added 0.06%	1,080,122 $1.14 Million
Q1 2022 May 13, 2022	SELL	$1.23 - $1.9 $10,082 - $15,574	-8,197 Reduced 0.75%	1,079,522 $1.92 Million
Q4 2021 Feb 14, 2022	BUY	$1.64 - $2.83 $56,837 - $98,079	34,657 Added 3.29%	1,087,719 $2.02 Million
Q3 2021 Nov 12, 2021	BUY	$2.7 - $3.59 $14,939 - $19,863	5,533 Added 0.53%	1,053,062 $3.16 Million
Q2 2021 Aug 13, 2021	BUY	$3.21 - $4.06 $3.36 Million - $4.25 Million	1,047,529 New	1,047,529 $3.84 Million

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $48.6M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.